Arthritis Monoclonal Antibodies Market Report 2024-2033: Size, Share, Growth, Trends, Analysis, Forecast, Outlook

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Arthritis Monoclonal Antibodies Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $83.76 billion In 2028 At A CAGR Of 7.7% :
The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2023 to $62.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding range of approved arthritis monoclonal antibodies, government support for research and development, increased investment from pharmaceutical companies.

The arthritis monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $83.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, advancements in drug delivery.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp

Arthritis Monoclonal Antibodies Market Major Segments
The arthritis monoclonal antibodies market covered in this report is segmented -
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hopitals, Research Institutes, Other End-Users

Key Driver - Arthritis Prevalence Fuels Growth In Arthritis Monoclonal Antibody Market

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Global RA Network, in 2021, Over 350 million individuals worldwide suffer from arthritis and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1%, and the worldwide estimates of osteoarthritis include 9.6% of men and 18% of women. The increased prevalence of arthritis and the demand for personalized medicine are increasing the demand for the market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=3449&type=smp

Prominent Trend - Advancements In Therapeutic Monoclonal Antibodies Revolutionize The Arthritis Treatment Landscape

The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target-specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

Arthritis Monoclonal Antibodies Market Players
Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Mylan N.V., Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the arthritis monoclonal antibodies market in 2023. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Arthritis Monoclonal Antibodies Market Report Structure
3. Arthritis Monoclonal Antibodies Market Trends And Strategies
4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario
5. Arthritis Monoclonal Antibodies Market Size And Growth
…..
27. Arthritis Monoclonal Antibodies Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.